-
www.monahrq.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-5-attach-1.pdf
January 01, 2009 - and other psychotic symptoms
associated with the use of attention-deficit/hyperactivity disorder drugs … Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-5-attach-1.pdf
January 01, 2009 - and other psychotic symptoms
associated with the use of attention-deficit/hyperactivity disorder drugs … Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
-
ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-5-attach-1.pdf
January 01, 2009 - and other psychotic symptoms
associated with the use of attention-deficit/hyperactivity disorder drugs … Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
-
www.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-5-attach-1.pdf
January 01, 2009 - and other psychotic symptoms
associated with the use of attention-deficit/hyperactivity disorder drugs … Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
-
effectivehealthcare.ahrq.gov/sites/default/files/searching.ppt
January 01, 2011 - Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008. … Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008. … or may be incompletely published elsewhere
Good check for publication bias
Regulatory Web sites:
Drugs … That is because the approval process for new drugs and devices requires submission of data that may not … Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008.
Sassi F, Archard L, McDaid D.
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/searching.ppt
January 01, 2011 - Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008. … Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008. … or may be incompletely published elsewhere
Good check for publication bias
Regulatory Web sites:
Drugs … That is because the approval process for new drugs and devices requires submission of data that may not … Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008.
Sassi F, Archard L, McDaid D.
-
www.ahrq.gov/research/findings/studies/index.html?page=238
January 01, 2024 - monitoring (PDMP) programs, which constitute a key policy targeting access to non-medical use of Rx drugs
-
psnet.ahrq.gov/issue/effort-human-factors-performance-and-decision-making
August 31, 2022 - Commentary
Effort in human factors performance and decision making.
Citation Text:
Wickens CD. Effort in human factors performance and decision making. Hum Factors. 2014;56(8):1329-36.
Copy Citation
Format:
Google Scholar PubMed BibTeX EndNote X3 XML EndNote 7 XML Endnote t…
-
psnet.ahrq.gov/issue/individual-based-framework-study-medical-error
November 11, 2020 - Commentary
An individual-based framework for the study of medical error.
Citation Text:
Veazie PJ. An individual-based framework for the study of medical error. Int J Qual Health Care. 2006;18(4):314-9.
Copy Citation
Format:
Google Scholar PubMed BibTeX EndNote X3 XML End…
-
psnet.ahrq.gov/issue/resistance-patient-safety-initiatives
November 26, 2014 - Newspaper/Magazine Article
Resistance to patient safety initiatives.
Citation Text:
O'Connor EJ, Fiol M. Resistance to patient safety initiatives. Physician executive. 2005;31(6):64-7.
Copy Citation
Format:
Google Scholar PubMed BibTeX EndNote X3 XML EndNote 7 XML Endnote…
-
psnet.ahrq.gov/node/50929/psn-pdf
February 26, 2020 - Discharged with IV antibiotics: When issues arise, who
manages the complications?
February 26, 2020
Donnelley M, Gintjee TJ, Go J. Discharged with IV antibiotics: When issues arise, who manages the
complications? PSNet [internet]. 2020.
https://psnet.ahrq.gov/web-mm/discharged-iv-antibiotics-when-issues-arise-who-…
-
psnet.ahrq.gov/web-mm/discharge-fumbles
September 09, 2009 - addition, his commentary does not include information regarding investigational or off-label use of pharmaceutical … products or medical devices.
-
psnet.ahrq.gov/web-mm/wrong-shot-error-disclosure
May 01, 2011 - addition, their commentary does not include information regarding investigational or off-label use of pharmaceutical … products or medical devices.
-
psnet.ahrq.gov/node/49450/psn-pdf
June 01, 2004 - addition, their commentary
does not include information regarding investigational or off-label use of pharmaceutical … products or
medical devices.
-
effectivehealthcare.ahrq.gov/sites/default/files/product/pdf/episodic-migraine-surveillance-report-1.pdf
March 01, 2022 - Results from included studies: KQ 2. nonsteroidal anti-inflammatory drugs ............ … Rimegepant 75 mg is more effective for migraine
than nonsteroidal anti-inflammatory drugs: post
hoc … Biohaven Pharmaceuticals I. … Biohaven Pharmaceuticals I. … CNS Drugs. 2020
Oct;34(10):1015-24. doi: 10.1007/s40263-020-
00753-1. PMID: 32857291.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/episodic-migraine-surveillance-report-1.pdf
June 01, 2022 - Results from included studies: KQ 2. nonsteroidal anti-inflammatory drugs ............ … Rimegepant 75 mg is more effective for migraine
than nonsteroidal anti-inflammatory drugs: post
hoc … Biohaven Pharmaceuticals I. … Biohaven Pharmaceuticals I. … CNS Drugs. 2020
Oct;34(10):1015-24. doi: 10.1007/s40263-020-
00753-1. PMID: 32857291.
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/episodic-migraine-surveillance-report-1.pdf
June 01, 2022 - Results from included studies: KQ 2. nonsteroidal anti-inflammatory drugs ............ … Rimegepant 75 mg is more effective for migraine
than nonsteroidal anti-inflammatory drugs: post
hoc … Biohaven Pharmaceuticals I. … Biohaven Pharmaceuticals I. … CNS Drugs. 2020
Oct;34(10):1015-24. doi: 10.1007/s40263-020-
00753-1. PMID: 32857291.
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/ZTMgupsEkCUuuPVpeGUm45
September 01, 2013 - Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive
Services Task Force Recommendation Statement
Virginia A. Moyer, MD, MPH, on behalf of the U.S. Preventive Services Task Force*
Description: Update of the 2004 U.S. Preventive Services Task
Force (USPSTF) recommendation on screening for and treatment …
-
effectivehealthcare-admin.ahrq.gov/products/colorectal-cancer-liver-metastases-therapies/research-protocol
December 01, 2019 - whereby the concentration of a drug is greatly reduced before it reaches the systemic circulation) of drugs … Chemoembolization drugs and embolic mixtures have also changed a great deal in the last ten years and
-
www.qualitymeasures.ahrq.gov/patient-safety/quality-measures/21st-century/index.html
June 01, 2018 - found that antibiotics are frequently over-prescribed, contributing to microbial resistance to these drugs